Expertise in
9
conditions

Dr. Connie S. Uzel

Southern Cancer Center PC
Daphne, AL
Expertise in
9
conditions
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Expertise in
9
conditions
OverviewInsuranceLocationsClinical Research

Overview

Connie Uzel is a Hematologist Oncology specialist and an Oncologist in Daphne, Alabama. Dr. Uzel is highly rated in 9 conditions, according to our data. Her top areas of expertise are Lung Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Uzel is currently accepting new patients.

Her clinical research consists of participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in AL
Hospital Affiliations
Usa Health Hca Providence Hospital, LLC
Springhill Medical Center
Mobile Infirmary Medical Center
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  UnitedHealthcare
  •  Humana

Locations

SOUTHERN CANCER CENTER PC
29653 Anchor Cross Blvd, Daphne, AL 36526
251-625-6896
Other Locations
SOUTHERN CANCER CENTER PC
3719 Dauphin St, Suite 102, Mobile, AL 36608
251-625-6896
SOUTHERN CANCER CENTER PC
6701 Airport Blvd, Mobile, AL 36608
251-625-6896

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: April 24, 2024
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
18
conditions
Dr. Joseph R. Jones
Hematology Oncology | Oncology | Hematology
Expertise in
18
conditions
Dr. Joseph R. Jones
Hematology Oncology | Oncology | Hematology

Southern Cancer Center PC

3719 Dauphin St, Suite 5, 
Mobile, AL 
 (15.9 mi)
251-625-6896
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Jones is a Hematologist Oncology specialist and an Oncologist in Mobile, Alabama. Dr. Jones is highly rated in 18 conditions, according to our data. His top areas of expertise are Primary Mediastinal B-Cell Lymphoma (PMBCL), Paget Disease of the Breast, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Jones is currently accepting new patients.

Expertise in
57
conditions
Dr. Rami S. Owera
Hematology Oncology | Hematology | Oncology
Expertise in
57
conditions
Dr. Rami S. Owera
Hematology Oncology | Hematology | Oncology

Woodlands Medical Specialists P A

1301 Belleville Ave, 
Brewton, AL 
 (57.2 mi)
850-696-4000
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rami Owera is a Hematologist Oncology specialist and a Hematologist in Brewton, Alabama. Dr. Owera is highly rated in 57 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Gastroesophageal Junction Cancer. Dr. Owera is currently accepting new patients.

Expertise in
20
conditions
Dr. William C. Mcevoy
Hematology Oncology | Oncology | Hematology
Expertise in
20
conditions
Dr. William C. Mcevoy
Hematology Oncology | Oncology | Hematology

Southern Cancer Center PC

6701 Airport Blvd, 
Mobile, AL 
 (19.7 mi)
251-625-6896
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Mcevoy is a Hematologist Oncology specialist and an Oncologist in Mobile, Alabama. Dr. Mcevoy is highly rated in 20 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Mcevoy is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile